Mailed nicotine replacement therapy — Competitive Intelligence Brief

Mailed nicotine replacement therapy (Mailed nicotine replacement therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy. Area: Smoking Cessation / Addiction Medicine.

marketed Nicotine replacement therapy Nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine Small molecule

Target snapshot

Mailed nicotine replacement therapy (Mailed nicotine replacement therapy) — Massachusetts General Hospital. Nicotine replacement therapy delivered by mail provides nicotine to reduce withdrawal symptoms and cravings during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mailed nicotine replacement therapy TARGET	Mailed nicotine replacement therapy	Massachusetts General Hospital	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
NicoDerm CQ Patch	NicoDerm CQ Patch	Chrono Therapeutics, Inc.	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicotine (2 mg)	Nicotine (2 mg)	GlaxoSmithKline	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine Polacrilex Gum (2 mg)	Nicotine Polacrilex Gum (2 mg)	University of Hawaii	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine Mini	Nicotine Mini	University of Wisconsin, Madison	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine patch - transdermal	Nicotine patch - transdermal	Johns Hopkins University	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Extended Duration Combination NRT	Extended Duration Combination NRT	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (combination)	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy class)

1. University of Wisconsin, Madison · 2 drugs in this class
2. Iowa City Veterans Affairs Medical Center · 1 drug in this class
3. Massachusetts General Hospital · 1 drug in this class
4. NYU Langone Health · 1 drug in this class
5. GlaxoSmithKline · 1 drug in this class
6. University of Hawaii · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Vermont · 1 drug in this class
9. Ottawa Heart Institute Research Corporation · 1 drug in this class